New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (November 15, 2023)
Chimeric antigen receptor (CAR) T-cell therapy has been approved by the US Food and Drug Administration and other regulatory agencies for patients with R/R DLBCL (including hi...